Gene expression profile (GEP) testing helps guide treatment decisions for women with early-stage breast cancer, according to a presentation from Veracyte at the European Society of Medical Oncology (ESMO) Breast Cancer 2022.
To generate consensus regarding the clinical utility in breast cancer treatment of GEP tests, including Veracyte's Prosigna breast cancer assay, 133 specialists from 11 European countries were surveyed in the PROCURE study.
The major findings of the PROCURE study include the following:
- 88% of participants give importance to GEP prognostic results when deciding on chemotherapy usage in the adjuvant setting for early-stage breast cancer patients whose disease has not spread to the lymph nodes
- 75% also consider it important when deciding on chemotherapy in the adjuvant setting in early-stage patients with one to three positive lymph nodes
- 76% of participants agree on the clinical utility of molecular subtype information from GEP testing to assess likelihood of disease recurrence among early-stage breast cancer patients who are hormone-receptor positive
- 75% think the use of molecular subtype information is useful in identifying patients who can safely avoid chemotherapy
